Peptide Product Composition: Understanding Glucagon Dosing
Abstract: Glucagon dosing precision is critical in peptide therapeutics, with market trends showing a 12.3% CAGR (2024–2030) driven by diabetes and congenital hyperinsulinism applications. Leading brands (e.g., Novo Nordisk, Eli Lilly) offer stable lyophilized formulations versus liquid-ready pens, balancing shelf-life (24–36 months) against injection convenience. Key technical parameters include reconstitution time (<2 min) and pH stability (3.5–4.5). Regulatory certifications (FDA, EMA, GMP) differentiate quality; factory audits verify peptide purity >98%. Logistics require cold-chain (2–8°C) compliance. Selection criteria prioritize indication-specific dosing (0.5–1 mg) and excipient compatibility. Industry data confirms glucagon’s expanding role in dual-hormone artificial pancreas systems.